3 results match your criteria dotazol

  • Page 1 of 1

Biodistribution and post-therapy dosimetric analysis of [Lu]Lu-DOTA in patients with osteoblastic metastases: first results.

EJNMMI Res 2019 Nov 28;9(1):102. Epub 2019 Nov 28.

Department of Nuclear Medicine, University Medical Center Bonn, Bonn, Germany.

Background: Preclinical biodistribution and dosimetric analysis of [Lu]Lu-DOTA suggest the bisphosphonate zoledronate as a promising new radiopharmaceutical for therapy of bone metastases. We evaluated biodistribution and normal organ absorbed doses resulting from therapeutic doses of [Lu]Lu-DOTA in patients with metastatic skeletal disease.

Method: Four patients with metastatic skeletal disease (age range, 64-83 years) secondary to metastatic castration-resistant prostate carcinoma or bronchial carcinoma were treated with a mean dose of 5968 ± 64 MBq (161. Read More

View Article and Full-Text PDF
November 2019

Preliminary results of biodistribution and dosimetric analysis of [Ga]Ga-DOTA: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases.

Ann Nucl Med 2019 Jun 15;33(6):404-413. Epub 2019 Mar 15.

Department of Nuclear Medicine, University Medical Center Bonn, Bonn, Germany.

Objective: Pre-clinical studies with gallium-68 zoledronate ([Ga]Ga-DOTA) have proposed it to be a potent bisphosphonate for PET/CT diagnosis of bone diseases and diagnostic counterpart to [Lu]Lu-DOTA and [Ac]Ac-DOTA. This study aims to be the first human biodistribution and dosimetric analysis of [Ga]Ga-DOTA.

Methods: Five metastatic skeletal disease patients (mean age: 72 years, M: F; 4:1) were injected with 150-190 MBq (4. Read More

View Article and Full-Text PDF

Evaluation of [Ac]Ac-DOTA for α-Therapy of Bone Metastases.

Curr Radiopharm 2018 ;11(3):223-230

Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany.

Background: Conjugates of bisphosphonates with macrocyclic chelators possess high potential in bone targeted radionuclide imaging and therapy. DOTAZOL, zoledronic acid conjugated to DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), demonstrated promising results in vivo in small animals as well as in first patient applications using 68Ga for diagnosis via PET and the lowenergy β-emitter 177Lu for therapy of painful bone metastases. In consideration of the fact that targeted α-therapy probably offers various advantages over the use of β--emitters, the 225Ac-labelled derivative [225Ac]Ac-DOTAZOL was synthesized and evaluated in vivo. Read More

View Article and Full-Text PDF
January 2019
  • Page 1 of 1